

Supplementary Table S1. Clinical profile of patients with primary Sjögren's syndrome with minimal change disease in our hospital and literature.

Patient No.	ANA	SSA [†]	ESSDAI [‡]	Age/Gender	Oedema	Haematuria	24h-Urine Protein (g/24h)	Serum albumin (g/L)	Scr (µmol/L)	eGFR (ml/min/1.73m ²)*	Treatment	Follow-up (3 month)	Relapse times
1	-	+	8	47/F	+	+	11.20	16	61	104	GCs + CTX	PR	1
2	1:160S	+	5	37/F	+	+	7.34	12	66	102	GCs	CR	0
3	1:80N	+	6	47/F	+	+	5.28	19.3	67	94	GCs+HCQ	CR	5
4	1:320SN	+	8	71/F	+	-	17.69	13	160	28	GCs	Loss	Loss
5	1:640S	+	5	44/F	+	+	19.02	13	151	36	GCs	PR	0
6	1:640S	+	6	60/M	+	+	3.70	16	77	94	GCs+ TII	CR	1
7	1:32	+	4	51/F	+	+	6.97	18	66	93	GCs	CR	0
8	-	+	8	50/M	+	+	20.87	20	146	48	GCs +CTX	CR	0
Maripuri 2009 (8)	NA	NA	NA	66/F	NA	NA	5.9	NA	114.9	44*	GCs +HCQ	CR	NA
Yang 2011 (9)	1:320S	+	NA	40/F	+	-	6.35	17.9	68.95	95	GCs	NA	NA
Kidder 2015 (10)	NA	NA	NA	39/F	NA	NA	NA	NA	50	126	HCQ	NA	NA

ANA: antinuclear antibodies; SSA: Sjögren-syndrome-related antigen A; ESSDAI: EULAR Sjögren's Syndrome Disease Activity Index; Scr: serum creatinine; eGFR: estimated glomerular filtration rate; GCs: glucocorticoids; CTX: cyclophosphamide; HCQ: hydroxychloroquine; TII: tripterygium wilfordii; PR: partial remission; CR: complete remission; NA: not available.

[†]All patients fulfilled the American-European Consensus Group criteria for primary Sjogren's Syndrome.

[‡]ESSDAI: containing 12 domains: constitutional, lymphadenopathy, glandular, articular, cutaneous, pulmonary, renal, muscular, PNS, CNS, haematological, biological. Score varied from 2 to 47.

*CKD-EPI method was used to calculate eGFR.